Mainz Biomed Balance Sheet Health

Financial Health criteria checks 2/6

Mainz Biomed has a total shareholder equity of $-4.1M and total debt of $6.9M, which brings its debt-to-equity ratio to -166.8%. Its total assets and total liabilities are $8.5M and $12.6M respectively.

Key information

-166.8%

Debt to equity ratio

US$6.90m

Debt

Interest coverage ration/a
CashUS$977.76k
Equity-US$4.14m
Total liabilitiesUS$12.59m
Total assetsUS$8.45m

Recent financial health updates

Recent updates

Mainz Biomed GAAP EPS of -$0.91, revenue of $0.24M beats by $0.14M

Sep 07

Mainz Biomed stock rises 22% on launch of colorectal cancer test in Italy, UAE

Aug 16

Mainz Biomed: Sharp Appreciation In Value Since IPO

Jan 26

Financial Position Analysis

Short Term Liabilities: MYNZ has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MYNZ has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MYNZ has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MYNZ's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MYNZ has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: MYNZ is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies